These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32815661)

  • 1. Pharmacological treatment of high-normal blood pressure (prehypertension) in high-risk patients for primary prevention of cardiovascular events.
    Borazjani R; Kojuri J; Abdi-Ardekani A; Izadpanah P; Dehghani P; Sayadi M; Attar A
    J Clin Hypertens (Greenwich); 2020 Sep; 22(9):1627-1634. PubMed ID: 32815661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial.
    Attar A; Sayadi M; Jannati M
    Eur J Prev Cardiol; 2019 Feb; 26(3):238-245. PubMed ID: 30256671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
    Blood Pressure Lowering Treatment Trialists' Collaboration
    Lancet; 2021 May; 397(10285):1625-1636. PubMed ID: 33933205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
    Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
    Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials.
    Oikonomou EK; Spatz ES; Suchard MA; Khera R
    Lancet Digit Health; 2022 Nov; 4(11):e796-e805. PubMed ID: 36307193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.
    ; Lewis CE; Fine LJ; Beddhu S; Cheung AK; Cushman WC; Cutler JA; Evans GW; Johnson KC; Kitzman DW; Oparil S; Rahman M; Reboussin DM; Rocco MV; Sink KM; Snyder JK; Whelton PK; Williamson JD; Wright JT; Ambrosius WT
    N Engl J Med; 2021 May; 384(20):1921-1930. PubMed ID: 34010531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. J-shaped relationship between cardiovascular risk and efficacy of intensive blood pressure reduction: A post-hoc analysis of the SPRINT trial.
    Attar A; Nouri F; Borazjani R; Sayadi M
    PLoS One; 2020; 15(10):e0240102. PubMed ID: 33002071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.
    Williamson JD; Supiano MA; Applegate WB; Berlowitz DR; Campbell RC; Chertow GM; Fine LJ; Haley WE; Hawfield AT; Ix JH; Kitzman DW; Kostis JB; Krousel-Wood MA; Launer LJ; Oparil S; Rodriguez CJ; Roumie CL; Shorr RI; Sink KM; Wadley VG; Whelton PK; Whittle J; Woolard NF; Wright JT; Pajewski NM;
    JAMA; 2016 Jun; 315(24):2673-82. PubMed ID: 27195814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The SPRINT Research. A Randomized Trial of Intensive versus Standard Blood-Pressure Control].
    Widimský J
    Vnitr Lek; 2016 Jan; 62(1):44-7. PubMed ID: 26967236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Associated With Failure to Achieve the Intensive Blood Pressure Target in the Systolic Blood Pressure Intervention Trial (SPRINT).
    Wang KM; Stedman MR; Chertow GM; Chang TI
    Hypertension; 2020 Dec; 76(6):1725-1733. PubMed ID: 33131314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
    Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
    JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S
    Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effects of Intensive Blood Pressure Control on Cardiovascular Outcomes Based on 10-Year ASCVD Risk Score: An Analysis of a Clinical Trial.
    Alborzi A; Attar A; Sayadi M; Nouri F
    Cardiol Res Pract; 2021; 2021():6635345. PubMed ID: 34055403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of baseline systolic blood pressure on the relationship between intensive blood pressure control and cardiovascular outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT).
    Sun X; Guo Y; Nie Z; Cheng J; Zhou H; Zhong X; Zhang S; Du Z; Zhuang X; Liao X
    Clin Res Cardiol; 2019 Mar; 108(3):273-281. PubMed ID: 30167807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
    Zhang L; Sun X; Liao L; Zhang S; Zhou H; Zhong X; Zhuang X; Liao X
    J Clin Hypertens (Greenwich); 2019 Dec; 21(12):1813-1820. PubMed ID: 31670874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
    Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
    Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morning Home Blood Pressure and Cardiovascular Events in Japanese Hypertensive Patients.
    Kario K; Iwashita M; Okuda Y; Sugiyama M; Saito I; Kushiro T; Teramukai S; Shimada K
    Hypertension; 2018 Oct; 72(4):854-861. PubMed ID: 30354719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Intensive Blood Pressure Control in Patients with Evident Cardiovascular Disease: An Investigation Using the SPRINT Study Data.
    Vlachopoulos C; Terentes-Printzios D; Aznaouridis K; Ioakeimidis N; Xaplanteris P; Lazaros G; Tousoulis D
    Curr Vasc Pharmacol; 2019; 17(3):298-306. PubMed ID: 29512468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
    Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
    PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
    Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
    PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.